March 25, 2017 11:54 AM ET

Healthcare Equipment and Supplies

Company Overview of Entellus Medical, Inc.

Company Overview

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use ...

3600 Holly Lane North

Suite 40

Plymouth, MN 55447

United States

Founded in 2006

280 Employees

Phone:

763-463-1595

Key Executives for Entellus Medical, Inc.

Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $442.5K
Compensation as of Fiscal Year 2015.

Entellus Medical, Inc. Key Developments

Entellus Medical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Provides Earnings Guidance for the First Quarter and Full Year of 2017

Entellus Medical, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported revenue of $21,672,000 against $18,073,000 a year ago. Loss from operations was $6,837,000 against $4,495,000 a year ago. Loss before income tax expense was $7,346,000 against $5,013,000 a year ago. Net loss was $7,318,000 against $5,013,000 a year ago. Basic and diluted net loss per share was $0.39 against $0.27 a year ago. The growth in revenue was attributable to increased demand for new products and an increase in sales of the company’s XprESS family of products through broader account penetration in both the office and the operating room (OR). Foreign currency exchange rates negatively impacted revenue by approximately $0.1 million for the quarter. For the year, the company reported revenue of $75,184,000 against $61,570,000 a year ago. Loss from operations was $26,715,000 against $15,856,000 a year ago. Loss before income tax expense was $28,724,000 against $18,300,000 a year ago. Net loss was $28,730,000 against $18,300,000 a year ago. Basic and diluted net loss per share was $1.53 against $1.06 a year ago. The growth in revenue was attributable to increased demand for new products and an increase in sales of the company’s XprESS family of products through broader account penetration in both the office and the OR, despite foreign currency exchange rates negatively impacting revenue by approximately $0.2 million for the year. International revenue was $3.5 million for 2016, compared to $659,000 in 2015. The company expects full year 2017 revenue will be in a range of $86 million to $90 million, representing growth of 14% to 20% over 2016 revenue. Gross margin is expected to be in a range of 72% to 74% for the full year 2017. Full year 2017 net loss is expected to be in a range of $24 million to $32 million. The company expects first quarter 2017 revenue will be in a range of $19 million to $20 million, representing growth of 12% to 18% over the first quarter of 2016. Gross margin is expected to be in a range of 72% to 74% for the first quarter of 2017. First quarter 2017 net loss is expected to be in a range of $9 million to $11 million.

Entellus Medical, Inc., Q4 2016 Earnings Call, Feb 21, 2017

Entellus Medical, Inc., Q4 2016 Earnings Call, Feb 21, 2017

Entellus Medical, Inc. to Report Q4, 2016 Results on Feb 21, 2017

Entellus Medical, Inc. announced that they will report Q4, 2016 results After-Market on Feb 21, 2017

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
June 29, 2016
CogENT Therapeutics, LLC
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Entellus Medical, Inc., please visit www.entellusmedical.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.